These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. New Injectable Drug for Type 2 Diabetes. Aschenbrenner DS Am J Nurs; 2016 Nov; 116(11):22-23. PubMed ID: 27787319 [No Abstract] [Full Text] [Related]
9. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. Trujillo JM; Goldman J Pharmacotherapy; 2017 Aug; 37(8):927-943. PubMed ID: 28556176 [TBL] [Abstract][Full Text] [Related]
10. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402 [TBL] [Abstract][Full Text] [Related]
11. Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus. Forst T Expert Opin Pharmacother; 2016 Aug; 17(12):1703-8. PubMed ID: 27341040 [TBL] [Abstract][Full Text] [Related]
12. [Not Available]. Salvador J; Gaztambide S Med Clin (Barc); 2014; 143 Suppl 2():1. PubMed ID: 25326835 [No Abstract] [Full Text] [Related]
13. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control]. Fernández-García JC; Colomo N; Tinahones FJ Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839 [TBL] [Abstract][Full Text] [Related]
14. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus. Hanefeld M; Raccah D; Monnier L Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453 [TBL] [Abstract][Full Text] [Related]
15. Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes. Scott LJ Drugs; 2017 Aug; 77(12):1353-1362. PubMed ID: 28667587 [TBL] [Abstract][Full Text] [Related]
16. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis. Peterson SC; Barry AR Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990 [TBL] [Abstract][Full Text] [Related]
17. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Blumer I; Pettus JH; Santos Cavaiola T Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Werner U; Haschke G; Herling AW; Kramer W Regul Pept; 2010 Sep; 164(2-3):58-64. PubMed ID: 20570597 [TBL] [Abstract][Full Text] [Related]
19. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus. Gupta A; Jelinek HF; Al-Aubaidy H Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496 [TBL] [Abstract][Full Text] [Related]
20. Management of Type 2 Diabetes in Acute Coronary Syndromes: Current State and Future Perspectives. Koufakis T; Karangelis D; Androutsopoulou V; Mikroulis D; Kotsa K Curr Pharm Des; 2023; 29(5):365-367. PubMed ID: 36762749 [No Abstract] [Full Text] [Related] [Next] [New Search]